Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
580 Court Street
Keene, NH 03431Phone+1 603-354-6570
Education & Training
Cleveland Clinic FoundationResidency, Urology, 1990 - 1996
Lewis Katz School of Medicine at Temple UniversityClass of 1990
Certifications & Licensure
NH State Medical License 2022 - 2026
NV State Medical License 1999 - 2023
FL State Medical License 1997 - 2002
OH State Medical License 1993 - 2001
MD State Medical License 1996 - 1998- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- 14 citationsCost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.Douglas Coyle, Roger A. Rodby, Steven D. Soroka, Adeera Levin, Norman Muirhead
Clinical Therapeutics. 2007-07-01 - 16 citationsIrbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuriaAndrew J. Palmer, Lieven Annemans, Stéphane Roze, Pablo Lapuerta, Roland N. Chen
Kidney International. Supplement. 2005-01-01 - 71 citationsComplications of laparoscopic procedures after concentrated training in urological laparoscopy.Jeffrey A. Cadeddu, J. Stuart Wolfe, Stephen Y. Nakada, Roland N. Chen, Arieh L. Shalhav
The Journal of Urology. 2001-12-01
Press Mentions
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to Be Presented at American Heart Association Scientific Sessions 2022November 2nd, 2022- Bristol Myers Squibb to Demonstrate the Strength of Its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific SessionMarch 21st, 2022
- Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction TherapyFebruary 16th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
